Distribution of traffic accidents by age, gender, and seat belt use. by Bayapa Reddy Narapureddy (11875358)

Distribution of Facial bone fractures associated with other body structures injuries. by Bayapa Reddy Narapureddy (11875358)

Consolidated Standards of Reporting Trials flow diagram for participants in the trial. by Tosi M. Mwakyandile (16408705)

Facial traumas considering seat belt use in victims. by Bayapa Reddy Narapureddy (11875358)

I Optimal design for optimization of Axitinib loaded Spanlastics. by Randa Mohammed Zaki (21637175)

ANOVA for I optimal design of Axitinib loaded Spanlastics. by Randa Mohammed Zaki (21637175)

Traffic accident victims by position in the vehicle, gender, and safety equipment. by Bayapa Reddy Narapureddy (11875358)

The kinetic release data of the optimized formula compared to drug suspension. by Randa Mohammed Zaki (21637175)

Composition of different formulations with their responses in I optimal design for optimization of Axitinib loaded Spanlastics. by Randa Mohammed Zaki (21637175)

The composition and validation of the optimized formula with its predicted responses according to I Optimal Design. by Randa Mohammed Zaki (21637175)

Changes in baseline CD4 count through week 12 and week 24 according to the linear regression model. by Tosi M. Mwakyandile (16408705)

Most frequently experienced adverse events among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Frequency of body traumas associated with facial traumas according to seat belt use. by Bayapa Reddy Narapureddy (11875358)

Distribution of multiple Injuries associated with seat belt use vs Age groups. by Bayapa Reddy Narapureddy (11875358)

Recovery from inactivation kinetics of I_to (i.e. the fastest inactivation component of the outward K⁺ currents) in WT and Kv4.2-/-cardiomyocyte. by Jie Liu (15128)

“…Note that Kv4.2-/- decreases I_to,f but not I_{to, s}.…”

Cumulative incidence of mortality and loss to follow-up (LTF) among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Fig 5 - by Torsten Schober (20485754)

Cumulative incidence of morbidity, loss to follow-up (LTF) and mortality among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Fig 4 - by Torsten Schober (20485754)

Median changes in CD4 count, platelet activation, immune activation, and exhaustion markers from baseline through week 12 and week 24. by Tosi M. Mwakyandile (16408705)